Mp03-18 Extended Follow-Up of the Adjustable Artificial Sphincter Victo in the Treatment of Male Urinary Incontinence After 68 Months: Results in a High-Volume Center

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Male Incontinence (MP03)1 May 2024MP03-18 EXTENDED FOLLOW-UP OF THE ADJUSTABLE ARTIFICIAL SPHINCTER VICTO IN THE TREATMENT OF MALE URINARY INCONTINENCE AFTER 68 MONTHS: RESULTS IN A HIGH-VOLUME CENTER Ghazal Ameli, Peter Weibl, and Wilhelm Alexander Hübner Ghazal AmeliGhazal Ameli , Peter WeiblPeter Weibl , and Wilhelm Alexander HübnerWilhelm Alexander Hübner View All Author Informationhttps://doi.org/10.1097/01.JU.0001009488.55564.85.18AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Victo is an adjustable artificial urinary sphincter (AUS), consisting of three parts which are preconnected. A pressure regulating balloon, a cuff, and a pump, which includes a self-sealing port for adjustment. The objective of the present study is to evaluate the efficiency and safety of the VICTO AUS in the treatment of male stress urinary incontinence (SUI). METHODS: A total of 116 patients were included between 9/2017 and 4/2023. The prospective part of the trial started on 1/2020 and is still ongoing, and the estimates end of the clinical trial is May 2025. This analysis should evaluate the safety and efficacy in an extended follow-up. In this cohort we included also high risks patients and patient with fragile urethra, only patients with neurogenic lower urinary tract dysfunctions were excluded. The fragile urethra was defined as previous procedure for SUI (n=36; 31%), prior pelvic irradiation (n=52; 45%) and procedure for bladder neck pathologies (n=25; 22%) or urethra strictures (n=10; 9%). High risk patients were defined as patients under androgen deprivation therapy (n=22; 19%), with diabetes (n=23; 20%) and patients with vascular disease (n=52; 45%) as these risk factors can have impact on postoperative outcomes and urethral erosion. Postoperatively a standardized 24-hour pad test and pad usage (p/d) were evaluated. To compare pre-and postoperative continence status nonparametric t test was used. A p-value of <.05 was defined as statistically significant. RESULTS: Median preoperative urine loss in the 24-hours pad test was 520 ml (min. 50- max. 2000) and was significantly improved at any point in follow-up. After a median follow-up of 32 months, 51% of the patients were totally dry (a maximum of 20 g in the 24-hour pad test), additionally 7,3% used only 1 p/d (in average 39.8 g) and were socially dry. In total 81% of the patients had an improved continence situation regarding p/d and 19% were classified as failed (<50% improvement). Regarding urine loss(g) in 24- hour pad use an improvement of ≥50% was observed in 84% of the patients. Erosion and infection were reported in 9,5% and a device dysfunction was described in 2,6%. CONCLUSIONS: An effectiveness can be demonstrated also in high-risk patients in an extended follow-up. The complication rate was comparable to the literature for AUS devices and the satisfaction rate was high. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e29 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Ghazal Ameli More articles by this author Peter Weibl More articles by this author Wilhelm Alexander Hübner More articles by this author Expand All Advertisement PDF downloadLoading ...